首页> 外文期刊>Biosensors & Bioelectronics: The International Journal for the Professional Involved with Research, Technology and Applications of Biosensers and Related Devices >Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, beta-M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis
【24h】

Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, beta-M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis

机译:使用荧光光谱技术与表面等离振子共振(SPR)分析的比较,基于多重磁性纳米粒子-抗体结合物(MNPs-ABS)对卵巢癌生物标志物,CA-125,β-M和ApoA1的预后检测

获取原文
获取原文并翻译 | 示例
           

摘要

A multiplexed MNPs-Abs based fluorescence spectroscopic system in analysis of serum biomarkers; CA-125, beta 2-M and ApoA1 for the early detection of ovarian cancer was first time proposed. The lowest detection limits measured in multiplexed setup were 0.26 U/mL, 0.55 ng/mL and 7.7 ng/mL respectively for CA-125, beta 2-M and ApoA1. A comparative real sample analysis of healthy normal (Control), benign and ovarian cancer patients with SPR has also been done to validate the process. Moreover CA-125 detection only confirms 50-60% of early stage disease. This multiplexed system achieved sensitivity and specificity up to 94% and 98% respectively to distinguish early stage ovarian cancer patients from healthy individuals. (C) 2015 Elsevier B.V. All rights reserved.
机译:基于多重MNPs-Abs的荧光光谱系统分析血清生物标志物;首次提出了CA-125,β2-M和ApoA1用于卵巢癌的早期检测。对于CA-125,β2-M和ApoA1,在多重设置中测得的最低检出限分别为0.26 U / mL,0.55 ng / mL和7.7 ng / mL。还对健康正常(对照),良性和卵巢癌的SPR患者进行了比较真实的样本分析,以验证该过程。此外,CA-125检测仅能确认50-60%的早期疾病。该多路复用系统分别达到了94%和98%的灵敏度和特异性,以区分早期卵巢癌患者和健康个体。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号